Patient Evaluation
Review diagnosis, disease status, medical history, prior treatment, current therapy and relevant comorbidities.
Clinical Leadership
Physician-led clinical oversight for regenerative and translational medicine.
CELLMEX clinical leadership provides the medical oversight connecting laboratory science, regenerative biotechnology and responsible patient care. Clinical decisions are physician-led and incorporate patient evaluation, available scientific evidence, biological-product characteristics, treatment rationale, safety considerations and structured follow-up.
Laboratory capability informs clinical medicine. It does not replace clinical judgment.
The Role of Clinical Leadership
Clinical governance extends beyond treatment administration
CELLMEX clinical leadership evaluates how developing regenerative technologies should—or should not—progress from laboratory investigation toward clinical consideration.
The physician's role includes assessment of the patient's underlying condition, review of conventional therapeutic alternatives, evaluation of the biological rationale for a proposed regenerative intervention, determination of clinical appropriateness, informed consent, treatment supervision and post-treatment follow-up.
Clinical governance also requires a clear distinction between laboratory observations, translational development, individual clinical care, structured clinical observation and formal human research.
Evidence Review
Assess the maturity, relevance and limitations of the scientific and clinical evidence supporting a proposed approach.
Protocol Development
Define appropriate clinical objectives, treatment rationale, monitoring parameters and follow-up requirements.
Risk–Benefit Assessment
Consider foreseeable risks, potential benefits, contraindications and available conventional alternatives.
Clinical Supervision
Maintain physician oversight of treatment planning, administration, immediate monitoring and clinical decision-making.
Follow-Up & Outcomes
Review safety, tolerability, clinical change, adverse events and continuing medical needs after treatment.
Lead Clinical Investigator
Physician oversight at the clinical–translational interface
Clinical leadership at CELLMEX is designed to maintain a clear boundary between scientific possibility and medically supportable patient care.
Dr. Giorgio Patino Cohen
Lead Clinical Investigator · CELLMEX Regenerative Medicine & Biotechnology
Dr. Giorgio Patino Cohen serves as Lead Clinical Investigator for CELLMEX, providing physician oversight of the clinical and translational interface between regenerative biotechnology, laboratory development and patient-directed medical care.
His responsibilities include clinical assessment of proposed regenerative applications, physician review of investigational biological technologies, development of clinical evaluation and follow-up frameworks, collaboration with laboratory and scientific personnel, and oversight of patient-specific medical decision-making.
Within the CELLMEX research model, his role is to help ensure that laboratory findings, biological mechanisms and emerging technologies are interpreted within their appropriate clinical context rather than being represented as established therapeutic benefit without sufficient supporting evidence.
Clinical Role
Lead Clinical Investigator
Primary Focus
Regenerative Medicine and Translational Biotechnology
Clinical Responsibilities
Patient evaluation, medical oversight, protocol development and follow-up
Research Interface
Cellular therapies, cell-free regenerative technologies and translational research
“Our responsibility is not simply to ask whether a biological technology can be produced, but whether there is sufficient scientific and clinical justification to consider its use in a particular patient.”
Clinical–Laboratory Interface
Connecting laboratory development with clinical medicine
CELLMEX maintains a deliberate distinction between biological development and clinical decision-making. Laboratory personnel characterize biological preparations and investigate biological behaviour under controlled conditions. Clinical leadership separately evaluates whether available scientific information provides an appropriate rationale for consideration within a specific medical context.
Laboratory Science
Translational Assessment
Physician Review
Patient Selection
Clinical Application
Follow-Up
A laboratory result alone does not determine patient treatment.
Laboratory findings may support biological plausibility or guide further investigation, but clinical decisions require independent medical interpretation together with patient history, diagnosis, therapeutic alternatives, safety considerations and the strength of available evidence.
How Clinical Decisions Are Made
Clinical decisions begin with the patient—not the biological product
Regenerative technologies should be considered within the complete clinical context of the individual patient rather than selected solely because a biological preparation is technically available.
Diagnosis & Medical Review
Confirm the patient's diagnosis, disease status, previous treatment, current therapy and present medical condition.
Standard-of-Care Review
Consider established therapies, alternatives and whether conventional treatment remains appropriate.
Scientific Rationale
Evaluate whether there is a biologically plausible and medically defensible rationale for the proposed regenerative approach.
Patient-Specific Risk Assessment
Consider comorbidities, medications, contraindications, administration route and foreseeable risks.
Informed Medical Decision
Discuss uncertainties, potential benefits, alternatives, limitations and follow-up requirements with the patient.
Follow-Up & Clinical Documentation
Monitor safety, tolerability, clinical response, adverse events and continuing medical needs.
Clinical Research Leadership
Clinical care, clinical observation and clinical research are distinct activities
CELLMEX clinical leadership distinguishes routine medical care, structured clinical observation, clinical research and formal controlled clinical trials. Each carries different scientific, ethical, documentation and regulatory requirements.
Human research requires formal scientific and ethical structure
Where a project constitutes formal human research, appropriate protocol development, ethical review, participant protection, data management, scientific analysis and applicable regulatory requirements must be considered.
Understand Our Research Framework →
Multidisciplinary Clinical Review
Complex cases may require multidisciplinary review
The composition of the clinical or scientific review team depends upon the patient's condition, the proposed biological technology and whether the activity represents clinical care, translational development or formal research.
Clinical Physicians
Provide diagnosis, treatment history, medical evaluation and patient-specific clinical judgment.
Laboratory Scientists
Contribute biological characterization, process information and laboratory interpretation.
Cell-Biotechnology Personnel
Support understanding of culture, processing, formulation, identity and biological-product characteristics.
Disease-Specific Specialists
Provide specialist expertise relevant to the patient's underlying disease or affected organ system.
Diagnostic & Imaging Specialists
Assist with objective baseline assessment and post-treatment evaluation where clinically relevant.
Quality & Regulatory Personnel
Participate where product quality, documentation, research classification or regulatory requirements warrant additional review.
Areas of Clinical and Translational Interest
Clinical leadership across developing regenerative platforms
These areas represent fields of clinical and translational interest and should not be interpreted as evidence that a particular technology has established efficacy for a specific disease.
Cellular Medicine
Conventional mesenchymal stromal cells and scientific investigation of lineage-directed cellular populations.
Cell-Free Regenerative Biology
Extracellular vesicles, small EVs, secretome, conditioned media and other cell-derived biological fractions.
Musculoskeletal Regeneration
Scientific and clinical evaluation involving cartilage, connective tissue and selected musculoskeletal applications.
Translational Biotechnology
Assessment of emerging biological processes and technologies for possible future clinical application.
Physician Collaboration
Development of physician-led evaluation, treatment, documentation and follow-up frameworks with collaborating clinicians.
Clinical Research Development
Translation of defined scientific questions into appropriately structured clinical or observational research pathways.
Patient Safety & Clinical Responsibility
Patient safety remains a clinical responsibility
Before a regenerative intervention is considered, clinical leadership evaluates the patient's diagnosis, medical history, concurrent therapy, potential contraindications, biological-product characteristics and available evidence. Clinical oversight also extends beyond the procedure itself.
Appropriate Patient Selection
Clinical eligibility should be based on diagnosis, medical condition and treatment rationale.
Informed Consent
Patients should understand proposed treatment, alternatives, uncertainties, potential risks and expected follow-up.
Medical Supervision
Regenerative interventions should occur under appropriate physician oversight and clinical monitoring.
Structured Follow-Up
Safety, tolerability, adverse events and clinical progress should be documented after treatment.
Emerging science must be identified as emerging science.
CELLMEX recognizes that regenerative medicine includes technologies at substantially different stages of scientific and clinical development. Mechanistic plausibility, laboratory evidence and individual clinical observations should not be represented as equivalent to evidence from adequately designed clinical studies.
Clinical leadership therefore considers both what is scientifically promising and what has actually been established.
Physician & Institutional Collaboration
Clinical collaboration with physicians and institutions
CELLMEX may collaborate with physicians, specialist practices, hospitals and scientific institutions in appropriately defined clinical, translational and research activities.
Clinical Collaboration
Patient referral, specialist consultation, clinical evaluation, treatment planning and structured follow-up.
Translational Research
Scientific collaboration involving biological rationale, laboratory findings, clinical questions and research development.
Protocol Development
Development of defined clinical objectives, patient criteria, monitoring plans, outcome measures and research documentation.
Biological-Product Evaluation
Clinical review of product characteristics, formulation, administration considerations and potential translational relevance.
Observational Data Development
Structured clinical documentation intended to improve understanding of safety, tolerability and patient outcomes.
Collaborative Research Projects
Defined projects involving clinicians, laboratories, academic investigators or other qualified scientific collaborators.
Clinical Leadership Enquiry
Contact CELLMEX clinical leadership
Physicians, institutions, research collaborators and professional organizations may use this form to initiate a clinical, scientific or translational enquiry.
Telephone
Location
Marina Vallarta, Puerto Vallarta, Jalisco, Mexico